Biopharma AI

Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?

Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…

ByByAnuja Singh Feb 28, 2026

Can Insilico Medicine and China Medical System Accelerate AI-Discovered Drugs from Algorithm to Clinic?

Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China Medical System Holdings…

ByByAnuja Singh Feb 28, 2026

Can Angelini’s $120M AI Alliance with Quiver Bioscience Redefine Drug Discovery in Genetic Epilepsies?

Executive SummaryIn a strategic push to strengthen its neuroscience pipeline, Angelini Pharma has entered a multiyear collaboration with…

ByByAnuja Singh Feb 28, 2026

Is Takeda’s $1.7B Bet on Iambic Therapeutics the Defining Moment for AI-Validated Drug Discovery?

Executive SummaryIn one of the largest AI-driven drug discovery collaborations to date, Takeda Pharmaceutical has entered a multiyear…

ByByAnuja Singh Feb 28, 2026
Image Not Found

Qure.ai Secures Landmark FDA Clearance for qXR-Detect, Cementing AI Leadership in Global Diagnostics—Brainlab Partnership Signals Agentic AI Workflow Revolution

Mumbai, India – March 4, 2026 – Qure.ai, a global leader in AI-powered radiology, today celebrated FDA clearance for…

ByByAnuja Singh Mar 4, 2026

Ardent Health’s Hellocare.ai Virtual Nursing Play: 20% Readmission Slash or AI Overreach in Care?

Ardent Health’s March 3-4, 2026, partnership with Hellocare.ai deploys AI modules for virtual nursing, telehealth, and real-time patient…

ByByAnuja Singh Mar 4, 2026
Scroll to Top